NYSE: PFE · General Drug Manufacturers

Pfizer (PFE) fair value: undervalued or overvalued?

As of 15 Nov 2026, Faircurve's model values Pfizer (PFE) at $33.13 a share. The stock last closed at $28.86, which puts the model's fair value 14.8% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Pfizer Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$33.13midpoint of 2,000 simulations
Last close$28.86NYSE: PFE
Gap to fair value+14.8%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 15 Nov 2026 moved the fair value from $33.64 to $33.13 (-1.5%).

What the model makes of itThe price of $28.86 is 14.8% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 2 Feb 2027. Options prices imply a move of about 8% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give PFE?

The calibrated range for PFE over 63 trading days is $26.21 to $31.93. It sits around the last close, and its width comes from the volatility that PFE's own options imply (29% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $20.17 to $50.49. In 59% of the simulations the fair value came out above the price the model ran on.

$9.61$88.87
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $33.13. Dashed line: the last close, $28.86.

Faircurve Insights · 15 Nov 2026

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing and distribution of medicinal and vaccine products worldwide.

Faircurve's model puts Pfizer's fair value at $33.13 a share, as of 15 Nov 2026. It is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $33.64, a move of -1.5%. The calibrated range over 63 trading days is $26.21 to $31.93, built around the price from the volatility the stock's own options imply. Calibrated weekly against realised prices, with 8,038 past valuations refreshed 14 Nov 2026, ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It reflects input completeness, the number of comparable companies and how closely they agree, and the spread of outcomes. It does not say whether the fair value is right.

Pfizer's overall quality score is 33 out of 100. Earnings quality is 84, with FCF / net income of 2.92x against a peer median of 0.85x. Growth quality is 18, with trailing revenue growth of -1.6% against a peer median of 6.0%. Balance sheet is 12, with net debt / EBITDA of 4.52x against a peer median of 1.21x. The model compares Pfizer with Gilead Sciences, Bristol-Myers Squibb, Amgen, Merck, AbbVie, Johnson & Johnson, Biogen and Eli Lilly.

Written from the figures on this page for the 15 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does PFE report earnings, and how has the stock reacted?

Pfizer's next earnings report is scheduled for 2 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 3.5% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. PFE's 30 day implied volatility works out to about 8.4% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across PFE's last 8 reports, ignoring direction, was 0.9%.

0%5%10%5.1%0.9%4 Feb '256.8%5.9%29 Apr '254.9%1.7%5 Aug '256.8%0.2%4 Nov '254.7%0.5%3 Feb '265.7%0.9%5 May '264.0%3.1%4 Aug '267.2%0.4%3 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in PFE

0%5%10%15%3 Nov '26 report4 Aug '26 report5 May '26 report3 Feb '26 report8% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 8% on 14 Nov 2025, reached 10% on 17 Apr 2026 and reads 8% on 16 Nov 2026. The marks are report dates.

How does PFE score on business quality?

Pfizer's overall quality score is 33 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.169.7%ROIC20.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).842.92xFCF / net income0.85x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.18-1.6%Revenue growth, trailing6.0%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.390.0%Net buybacks / market value0.9%
Balance sheetNet debt to EBITDA and interest coverage.124.52xNet debt / EBITDA1.21x
StabilityDownside volatility of the EBITDA margin over the last five years.226.4 ptsEBITDA margin downside volatility, 5y5.5 pts

How does PFE compare with similar companies?

The companies in general drug manufacturers closest to Pfizer in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
GILD Gilead Sciences, Inc.$167.58$219.16+30.8%Undervalued
BMY Bristol-Myers Squibb Company$62.93$68.95+9.6%Fairly valued
AMGN Amgen Inc.$462.32$479.14+3.6%Fairly valued
MRK Merck & Co., Inc.$144.46$126.11-12.7%Fairly valued
ABBV AbbVie Inc.$294.55$298.37+1.3%Fairly valued
JNJ Johnson & Johnson$282.55$226.25-19.9%Overvalued
BIIB Biogen Inc.$251.65$256.53+1.9%Fairly valued
LLY Eli Lilly and Company$1,431.67$1,125.83-21.4%Overvalued

What the comparable companies' multiples alone would give for PFE, the peer-implied price, is $38.61 a share on this run. The fair value weighs that against the company's own multiple.

All general drug manufacturer stocks ranked by gap to fair value

Pfizer at a glance

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide.

Market value
$164.7B
Sector
Healthcare
Industry
General Drug Manufacturers
Revenue expected, next twelve months
$61.0B
Consensus revenue growth, next fiscal year
+0.9%
Analysts with estimates
13
Beta to the US market
0.17
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. PFE was among them.

How the fair value is worked out: the model prices Pfizer on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for PFE was $33.64. As of 15 Nov 2026 it is $33.13, a change of -1.5%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Pfizer's valuation

Is Pfizer stock undervalued or overvalued?

On Faircurve's model, PFE reads as Fairly valued as of 15 Nov 2026. The model's fair value is $33.13 a share against a last close of $28.86, a gap of +14.8%.

What is PFE's fair value?

$33.13 a share as of 15 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $20.17 to $50.49.

What price range does the model give PFE?

$26.21 to $31.93 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Pfizer report earnings next?

The next report is scheduled for 2 Feb 2027. Companies can move their dates.

How much has PFE moved on past earnings reports?

Across its last 8 reports the median two session move was 0.9%, ignoring direction. The largest was +5.9% around the report of 29 Apr 2025.

How confident is the model in this valuation?

The model's evidence grade for PFE is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on PFE

The model holds no idea open on PFE today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on PFE with their outcomes. A free account is enough.

Keep reading